Uptake of atrial natriuretic peptide and production of cGMP in cultured human glomerular endothelial cells

Dollie F Green, Valentine A. Duruibe, Gershwin Blyden, Rachel E. Laskey, Jacques J. Bourgoignie

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Interactions between human glomerular endothelial cells and atrial natriuretic peptide (ANP) were studied with 125I-α-human-ANP binding and intracellular accumulation of cGMP. Uptake for α-hANP (1-28 or 5-28) by homogeneous cultures of human glomerular endothelial cells was dose and time dependent with optimal uptake occurring after 30 min of incubation at 37°C. Scatchard analysis of the specific binding data with a two-compartment model identified both high (Kd = 0.3 nM)- and low (Kd = 10 nM)-affinity receptors, with a binding site density of 12,000 and 18,060 receptors per cell, respectively. α-hANP markedly stimulated glomerular endothelial cell-associated cGMP. After a 2-min incubation, cGMP increased 1.3-fold (from 17.88 ± 1.29 to 23.33 ± 3 pmol/mg of protein), in the presence of 1 nM ANP, to more than threefold (from 21 ± .1 to 80.5 ± 14.5 pmol/mg of protein) with 1 μM ANP (P < 0.05). In contrast, a 10 μM concentration of the clearance receptor C-ANP4-23 increased cGMP by 1.6 ± 0.6 fold. ANP stimulation of intracellular cGMP was 100 times more sensitive in human glomerular endothelial than in mesangial cells. In comparison, higher doses of bradykinin were necessary to evoke similar responses in glomerular endothelial cells. In the presence of 10 μM bradykinin, cellular cGMP increased by 1.75 ± 0.6-fold versus control cells. However, unlike ANP, bradykinin-stimulated cGMP synthesis was significantly inhibited by prior treatment with oxyhemoglobin (10-5 M), an inhibitor of soluble guanylate cyclase, and NG-nitro-L-arginine (NO2Arg), a specific inhibitor of endothelial-derived relaxing factor (EDRF). ANP-stimulated cGMP synthesis was also attenuated in the presence of both hemoglobin and NO2Arg; however, the difference was not significant compared with ANP alone. In addition, α-hANP had no effect on intracellular free calcium or the accumulation of cAMP. In summary, human glomerular endothelial cells possess both high- and low-affinity binding sites for ANP, which respond by the activation of guanylate cyclase. The attenuation of ANP-stimulated cGMP synthesis in vitro by specific blockers of EDRF suggests that locally released EDRF may modulate the cellular effects of ANP.

Original languageEnglish
Pages (from-to)1091-1098
Number of pages8
JournalJournal of the American Society of Nephrology
Volume5
Issue number4
StatePublished - Oct 1 1994

Fingerprint

Atrial Natriuretic Factor
Endothelial Cells
Nitroarginine
Bradykinin
Binding Sites
Oxyhemoglobins
Mesangial Cells
Guanylate Cyclase
Hemoglobins
Proteins
Calcium

Keywords

  • Atrial natriuretic peptide receptors
  • cAMP
  • cGMP
  • Endothelium
  • Human glomerulus
  • Intracellular calcium

ASJC Scopus subject areas

  • Nephrology

Cite this

Green, D. F., Duruibe, V. A., Blyden, G., Laskey, R. E., & Bourgoignie, J. J. (1994). Uptake of atrial natriuretic peptide and production of cGMP in cultured human glomerular endothelial cells. Journal of the American Society of Nephrology, 5(4), 1091-1098.

Uptake of atrial natriuretic peptide and production of cGMP in cultured human glomerular endothelial cells. / Green, Dollie F; Duruibe, Valentine A.; Blyden, Gershwin; Laskey, Rachel E.; Bourgoignie, Jacques J.

In: Journal of the American Society of Nephrology, Vol. 5, No. 4, 01.10.1994, p. 1091-1098.

Research output: Contribution to journalArticle

Green, DF, Duruibe, VA, Blyden, G, Laskey, RE & Bourgoignie, JJ 1994, 'Uptake of atrial natriuretic peptide and production of cGMP in cultured human glomerular endothelial cells', Journal of the American Society of Nephrology, vol. 5, no. 4, pp. 1091-1098.
Green, Dollie F ; Duruibe, Valentine A. ; Blyden, Gershwin ; Laskey, Rachel E. ; Bourgoignie, Jacques J. / Uptake of atrial natriuretic peptide and production of cGMP in cultured human glomerular endothelial cells. In: Journal of the American Society of Nephrology. 1994 ; Vol. 5, No. 4. pp. 1091-1098.
@article{6504660fce2c43118d7e22e379ebf765,
title = "Uptake of atrial natriuretic peptide and production of cGMP in cultured human glomerular endothelial cells",
abstract = "Interactions between human glomerular endothelial cells and atrial natriuretic peptide (ANP) were studied with 125I-α-human-ANP binding and intracellular accumulation of cGMP. Uptake for α-hANP (1-28 or 5-28) by homogeneous cultures of human glomerular endothelial cells was dose and time dependent with optimal uptake occurring after 30 min of incubation at 37°C. Scatchard analysis of the specific binding data with a two-compartment model identified both high (Kd = 0.3 nM)- and low (Kd = 10 nM)-affinity receptors, with a binding site density of 12,000 and 18,060 receptors per cell, respectively. α-hANP markedly stimulated glomerular endothelial cell-associated cGMP. After a 2-min incubation, cGMP increased 1.3-fold (from 17.88 ± 1.29 to 23.33 ± 3 pmol/mg of protein), in the presence of 1 nM ANP, to more than threefold (from 21 ± .1 to 80.5 ± 14.5 pmol/mg of protein) with 1 μM ANP (P < 0.05). In contrast, a 10 μM concentration of the clearance receptor C-ANP4-23 increased cGMP by 1.6 ± 0.6 fold. ANP stimulation of intracellular cGMP was 100 times more sensitive in human glomerular endothelial than in mesangial cells. In comparison, higher doses of bradykinin were necessary to evoke similar responses in glomerular endothelial cells. In the presence of 10 μM bradykinin, cellular cGMP increased by 1.75 ± 0.6-fold versus control cells. However, unlike ANP, bradykinin-stimulated cGMP synthesis was significantly inhibited by prior treatment with oxyhemoglobin (10-5 M), an inhibitor of soluble guanylate cyclase, and NG-nitro-L-arginine (NO2Arg), a specific inhibitor of endothelial-derived relaxing factor (EDRF). ANP-stimulated cGMP synthesis was also attenuated in the presence of both hemoglobin and NO2Arg; however, the difference was not significant compared with ANP alone. In addition, α-hANP had no effect on intracellular free calcium or the accumulation of cAMP. In summary, human glomerular endothelial cells possess both high- and low-affinity binding sites for ANP, which respond by the activation of guanylate cyclase. The attenuation of ANP-stimulated cGMP synthesis in vitro by specific blockers of EDRF suggests that locally released EDRF may modulate the cellular effects of ANP.",
keywords = "Atrial natriuretic peptide receptors, cAMP, cGMP, Endothelium, Human glomerulus, Intracellular calcium",
author = "Green, {Dollie F} and Duruibe, {Valentine A.} and Gershwin Blyden and Laskey, {Rachel E.} and Bourgoignie, {Jacques J.}",
year = "1994",
month = "10",
day = "1",
language = "English",
volume = "5",
pages = "1091--1098",
journal = "Journal of the American Society of Nephrology",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "4",

}

TY - JOUR

T1 - Uptake of atrial natriuretic peptide and production of cGMP in cultured human glomerular endothelial cells

AU - Green, Dollie F

AU - Duruibe, Valentine A.

AU - Blyden, Gershwin

AU - Laskey, Rachel E.

AU - Bourgoignie, Jacques J.

PY - 1994/10/1

Y1 - 1994/10/1

N2 - Interactions between human glomerular endothelial cells and atrial natriuretic peptide (ANP) were studied with 125I-α-human-ANP binding and intracellular accumulation of cGMP. Uptake for α-hANP (1-28 or 5-28) by homogeneous cultures of human glomerular endothelial cells was dose and time dependent with optimal uptake occurring after 30 min of incubation at 37°C. Scatchard analysis of the specific binding data with a two-compartment model identified both high (Kd = 0.3 nM)- and low (Kd = 10 nM)-affinity receptors, with a binding site density of 12,000 and 18,060 receptors per cell, respectively. α-hANP markedly stimulated glomerular endothelial cell-associated cGMP. After a 2-min incubation, cGMP increased 1.3-fold (from 17.88 ± 1.29 to 23.33 ± 3 pmol/mg of protein), in the presence of 1 nM ANP, to more than threefold (from 21 ± .1 to 80.5 ± 14.5 pmol/mg of protein) with 1 μM ANP (P < 0.05). In contrast, a 10 μM concentration of the clearance receptor C-ANP4-23 increased cGMP by 1.6 ± 0.6 fold. ANP stimulation of intracellular cGMP was 100 times more sensitive in human glomerular endothelial than in mesangial cells. In comparison, higher doses of bradykinin were necessary to evoke similar responses in glomerular endothelial cells. In the presence of 10 μM bradykinin, cellular cGMP increased by 1.75 ± 0.6-fold versus control cells. However, unlike ANP, bradykinin-stimulated cGMP synthesis was significantly inhibited by prior treatment with oxyhemoglobin (10-5 M), an inhibitor of soluble guanylate cyclase, and NG-nitro-L-arginine (NO2Arg), a specific inhibitor of endothelial-derived relaxing factor (EDRF). ANP-stimulated cGMP synthesis was also attenuated in the presence of both hemoglobin and NO2Arg; however, the difference was not significant compared with ANP alone. In addition, α-hANP had no effect on intracellular free calcium or the accumulation of cAMP. In summary, human glomerular endothelial cells possess both high- and low-affinity binding sites for ANP, which respond by the activation of guanylate cyclase. The attenuation of ANP-stimulated cGMP synthesis in vitro by specific blockers of EDRF suggests that locally released EDRF may modulate the cellular effects of ANP.

AB - Interactions between human glomerular endothelial cells and atrial natriuretic peptide (ANP) were studied with 125I-α-human-ANP binding and intracellular accumulation of cGMP. Uptake for α-hANP (1-28 or 5-28) by homogeneous cultures of human glomerular endothelial cells was dose and time dependent with optimal uptake occurring after 30 min of incubation at 37°C. Scatchard analysis of the specific binding data with a two-compartment model identified both high (Kd = 0.3 nM)- and low (Kd = 10 nM)-affinity receptors, with a binding site density of 12,000 and 18,060 receptors per cell, respectively. α-hANP markedly stimulated glomerular endothelial cell-associated cGMP. After a 2-min incubation, cGMP increased 1.3-fold (from 17.88 ± 1.29 to 23.33 ± 3 pmol/mg of protein), in the presence of 1 nM ANP, to more than threefold (from 21 ± .1 to 80.5 ± 14.5 pmol/mg of protein) with 1 μM ANP (P < 0.05). In contrast, a 10 μM concentration of the clearance receptor C-ANP4-23 increased cGMP by 1.6 ± 0.6 fold. ANP stimulation of intracellular cGMP was 100 times more sensitive in human glomerular endothelial than in mesangial cells. In comparison, higher doses of bradykinin were necessary to evoke similar responses in glomerular endothelial cells. In the presence of 10 μM bradykinin, cellular cGMP increased by 1.75 ± 0.6-fold versus control cells. However, unlike ANP, bradykinin-stimulated cGMP synthesis was significantly inhibited by prior treatment with oxyhemoglobin (10-5 M), an inhibitor of soluble guanylate cyclase, and NG-nitro-L-arginine (NO2Arg), a specific inhibitor of endothelial-derived relaxing factor (EDRF). ANP-stimulated cGMP synthesis was also attenuated in the presence of both hemoglobin and NO2Arg; however, the difference was not significant compared with ANP alone. In addition, α-hANP had no effect on intracellular free calcium or the accumulation of cAMP. In summary, human glomerular endothelial cells possess both high- and low-affinity binding sites for ANP, which respond by the activation of guanylate cyclase. The attenuation of ANP-stimulated cGMP synthesis in vitro by specific blockers of EDRF suggests that locally released EDRF may modulate the cellular effects of ANP.

KW - Atrial natriuretic peptide receptors

KW - cAMP

KW - cGMP

KW - Endothelium

KW - Human glomerulus

KW - Intracellular calcium

UR - http://www.scopus.com/inward/record.url?scp=0028522445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028522445&partnerID=8YFLogxK

M3 - Article

C2 - 7849248

AN - SCOPUS:0028522445

VL - 5

SP - 1091

EP - 1098

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

SN - 1046-6673

IS - 4

ER -